| Dokumentenart: | Artikel | ||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Cancer | ||||||||||||||||||||||||||||||||||||||||||||||
| Verlag: | JOHN WILEY & SONS INC | ||||||||||||||||||||||||||||||||||||||||||||||
| Ort der Veröffentlichung: | HOBOKEN | ||||||||||||||||||||||||||||||||||||||||||||||
| Band: | 98 | ||||||||||||||||||||||||||||||||||||||||||||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 12 | ||||||||||||||||||||||||||||||||||||||||||||||
| Seitenbereich: | S. 2678-2686 | ||||||||||||||||||||||||||||||||||||||||||||||
| Datum: | 2003 | ||||||||||||||||||||||||||||||||||||||||||||||
| Institutionen: | Medizin > Lehrstuhl für Neurologie Medizin > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT) | ||||||||||||||||||||||||||||||||||||||||||||||
| Identifikationsnummer: |
| ||||||||||||||||||||||||||||||||||||||||||||||
| Klassifikation: |
| ||||||||||||||||||||||||||||||||||||||||||||||
| Stichwörter / Keywords: | MALIGNANT GLIOMA; PHASE-II; CLINICAL-TRIALS; PCV CHEMOTHERAPY; MULTIFORME; TEMOZOLOMIDE; ASTROCYTOMA; SURVIVAL; CRITERIA; RELAPSE; glioblastoma; disease recurrence; salvage therapy reintervention | ||||||||||||||||||||||||||||||||||||||||||||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Veröffentlicht | ||||||||||||||||||||||||||||||||||||||||||||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||||||||||||||||||||||||||||||||||||||||||||
| An der Universität Regensburg entstanden: | Ja | ||||||||||||||||||||||||||||||||||||||||||||||
| Dokumenten-ID: | 29345 |
Web of ScienceZusammenfassung
BACKGROUND. Survival after first-line therapy is poor for patients with glioblastoma. The role of second-line treatment for recurrent disease is controversial. The authors studied the outcome in a subset of patients with glioblastoma who were selected for an aggressive reintervention strategy at the time of progression. Their objectives were to improve patients' overall survival with sustained ...
Zusammenfassung
BACKGROUND. Survival after first-line therapy is poor for patients with glioblastoma. The role of second-line treatment for recurrent disease is controversial. The authors studied the outcome in a subset of patients with glioblastoma who were selected for an aggressive reintervention strategy at the time of progression. Their objectives were to improve patients' overall survival with sustained quality of life and to make comparisons with overall survival in unselected patients. METHODS. overall, 168 patients were eligible for retrospective analysis. Ninety patients received specific therapy for disease recurrence (reintervention group) by specific criteria. RESULTS. in the reintervention group, promising median overall survival (mOS) results after diagnosis (61.5 weeks) and progression (33 weeks) were obtained. The progression-free survival (PFS) rate at 12 months and the overall survival rate were superior in the reintervention group (71% at 12 months and 32% at 24 months). compared with the total cohort (45% and 20%, respectively) and the standard group (15% and 5%, respectively). A matched-pair analysis (n = 46 in each group), with an mOS period of 65.5 versus 28.5 weeks, confirmed these data. Quality of life was stable or slightly improved during reinterventions in a subset of patients treated within clinical studies. CONCLUSIONS. The majority of patients in the current series were treated with a reintervention strategy, which had an impact on PFS and mOS. A second resection, focal radiotherapy (in selected cases), and additional chemotherapeutic regimens should be considered for patients with recurrent glioblastoma. (D 2003 American Cancer Society.
Metadaten zuletzt geändert: 29 Sep 2021 07:39
Altmetric